Clinical Trial Update: LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy [Phase 3]

View source ↗

Summary

Phase III trial comparing afatinib versus erlotinib in squamous cell non-small cell lung cancer after platinum-based therapy; results completed and posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Afatinib (afatinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2014-11-21